TILDRAKIZUMAB, A SELECTIVE IL-23P19 ANTIBODY, IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS: RESULTS FROM TWO RANDOMIZED, CONTROLLED, PHASE 3 TRIALS

被引：0

作者：

Sinclair, R. ^{[1
]}

Reich, K. ^{[2
,3
]}

Papp, K. ^{[4
]}

Blauvelt, A. ^{[5
]}

Tyring, S. ^{[6
]}

Thaci, D. ^{[7
]}

Cichanowitz, N. ^{[8
]}

Mehta, A. ^{[8
]}

Li, Q. ^{[8
]}

Liu, K. ^{[8
]}

La Rosa, C. ^{[8
]}

Green, S. ^{[8
]}

Kimball, A. ^{[9
]}

机构：

[1] Univ Melbourne, Melbourne, Vic, Australia

[2] Sciderm Res Inst, Hamburg, Germany

[3] Dermatologikum Hamburg, Hamburg, Germany

[4] Prob Med Res, Waterloo, ON, Canada

[5] Oregon Med Res Ctr, Tigard, OR USA

[6] Univ Texas, Austin, TX USA

[7] Univ Lubeck, Lubeck, Germany

[8] Merck & Co Inc, Kenilworth, NJ USA

[9] Harvard Med Sch, Boston, MA USA

来源：

INTERNATIONAL JOURNAL OF DERMATOLOGY | 2017年 / 56卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

0177

引用

页码：1238 / 1239

页数：2

共 50 条

[1] Tildrakizumab, a selective IL-23p19 antibody, in the treatment of chronic plaque psoriasis: Results from two randomised, controlled, phase 3 trials
Sinclair, R.
Reich, K.
Papp, K.
Tyring, S. S.
Thaci, D.
Cichanowitz, N.
Blauvelt, A.
Liu, K.
Li, Q.
La Rosa, C.
Green, S. A.
Kimball, A. B.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 9 - 10
[2] Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis
Paton, D. M.
DRUGS OF TODAY, 2018, 54 (07) : 433 - 444
[3] Immunogenicity with tildrakizumab, an anti-IL-23p19 monoclonal antibody, in a pooled analysis of three randomized controlled trials in patients with chronic plaque psoriasis
Reich, Kristian
Kimball, Alexa B.
Li, Qing
van Aarle, Frank
Kerbusch, Thomas
Montgomery-Rodriguez, Diana Maria
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB157 - AB157
[4] Safety of selective IL-23p19 inhibitors for the treatment of psoriasis
Crowley, J. J.
Warren, R. B.
Cather, J. C.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (09) : 1676 - 1684
[5] Immunogenicity with tildrakizumab, an anti-interleukin-23p19 monoclonal antibody, in a pooled analysis of three randomized controlled trials in patients with chronic plaque psoriasis
Kimball, A.
Blauvelt, A.
Reich, K.
Li, Q.
van Aarle, F.
Kerbusch, T.
Montgomery, D.
BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E252 - E253
[6] Exposure-response analyses from a phase 2b and two phase 3 randomized controlled trials of tildrakizumab for the treatment of chronic plaque psoriasis
Kerbusch, Thomas
Li, Hanbin
Wada, David
Wenning, Larissa
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB139 - AB139
[7] Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Reich, Kristian
Papp, Kim A.
Blauvelt, Andrew
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Nograles, Kristine
Mehta, Anish
Cichanowitz, Nicole
Li, Qing
Liu, Kenneth
La Rosa, Carmen
Green, Stuart
Kimball, Alexa B.
LANCET, 2017, 390 (10091): : 276 - 288
[8] Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis
Xu, Shanshan
Zhang, Xiaoyi
Pan, Meijuan
Shuai, Zongwen
Xu, Shengqian
Pan, Faming
INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 75
[9] TREATMENT WITH TILDRAKIZUMAB, AN ANTI-IL-23P19 MONOCLONAL ANTIBODY, IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS
Thaci, D.
Papp, K.
Reich, K.
Langley, R. G.
Mehta, A.
Li, Q.
La Rosa, C.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 597 - 597
[10] Alefacept treatment results in clinically meaningful improvement in patients with chronic plaque psoriasis: Results from two randomized, placebo-controlled phase III trials
Balkrishnan, R
Feldman, SR
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 121 (06) : 1569 - 1569

← 1 2 3 4 5 →